Devanshu Singla

Why did Systematix initiate coverage on JTEKT India? 33% upside seen

Systematix has set a target price of ₹192 for JTEKT India, valuing the stock at EV/Ebitda of 17.5 times on December 2027E, in line with its past five-year average multiple

Anand Rathi starts coverage on Jubilant Ingrevia with 'Buy'; check target

Anand Rathi expects Jubilant's capex cycle to drive a sharp earnings upturn over FY26-28, with consolidated Ebitda seen growing at around a 22 per cent CAGR

Aarti Industries stock set to rise? PL Capital upgrades to 'Accumulate'

PL Capital has maintained the target price at ₹403 for Aarti Industries, valuing the stock at 24 times September 2027 estimated earnings per share (EPS)

Motilal Oswal expects revival in luggage sector; retains Buy on VIP, Safari

Motilal Oswal expects improved margin stability across the sector, aided by moderation in discounting and a strategic shift towards profitability

Gujarat Kidney IPO: Fair valuations, analysts cautious; should you bid?

The three-day subscription window to bid for the Gujarat Kidney IPO will close on Wednesday, December 24, 2025

Pre-listing hype or real gains? What 2025's IPO numbers say about GMPs

Companies raised a total of ₹1.74 trillion (₹1,74,379 crore) through 101 mainboard initial public offerings, making the year a landmark for equity fundraising

Elara Securities sees up to 60% upside in BEML stock price; here's why

Elara Securities has maintained a 'Buy' on the stock, citing expected double-digit earnings growth during FY25-28E, and a rising order pipeline ensuring steady revenue visibility

ICICI Pru AMC makes solid debut, analysts upbeat on long-term; here's why

Domestic brokerages Equirus Securities and PL Capital have initiated coverage on ICICI Prudential Asset Management Company

Nuvama downgrades SAIL to 'Reduce' on weak steel margins, rising debt

Nuvama Institutional Equities has downgraded the Steel Authority of India (SAIL) to 'Reduce', flagging concerns around excess flat steel supply in India and weak steel margins

PL Capital starts with 'Buy' on ICICI Pru AMC ahead of listing; target here

Analysts at PL Capital expect ICICI Prudential AMC's equity AAuM to grow at a CAGR that is 2.5 per cent higher than the industry average over FY25-28

ICICI Sec starts coverage on Leela Palaces with 'Buy'; 45% upside seen

ICICI Securities has set a target price of ₹600 for Leela Palaces Hotels and Resorts, based on a 22x EV/Ebitda on December 2027 earnings estimates for its hotels business

Motilal Oswal retains Buy on Vishal Mega Mart, sees 25% upside; here's why

MOFSL said Vishal Mega Mart's management remains optimistic about sustaining double-digit Same Store Sales Growth on an annual basis for a fairly long period

Why a 70:30 gold-silver mix works best for investors, explains Pratik Oswal

Investors are increasingly using index funds as long-term wealth-creation vehicles rather than for short tactical exposure, Oswal said

Axis Capital starts coverage on ONGC with 'Sell'; sees 14% downside

Axis Capital has initiated coverage on ONGC with a 'Sell' rating, citing concerns over production, oil prices, and subsidiary debt

KSH International IPO: Solid growth, analysts stay neutral; should you bid?

SBI Securities has maintained a "Neutral" view on the KSH International IPO and would like to monitor its performance post-listing

KSH International IPO opens Dec 16; key risks, strengths you must know

KSH International IPO will be offered at a price band of ₹365 to ₹384 per share and the lot size has been set at 39 shares

ICICI Prudential AMC IPO opens: Analysts suggest long-term buy; here's why

ICICI Prudential AMC IPO: Analysts at Canara Bank Securities and Anand Rathi have recommended subscribing to the issue from a long-term perspective

Park Medi World vs Nephrocare Health IPO: Where should you park your money?

Analysts broadly have a positive view of Park Medi World, given the strong outlook for India's healthcare delivery market and the company's expansion strategy

Meesho lists at 46% premium; analysts upbeat on long-term view; here's why

Choice Equity Broking has initiated coverage on Meesho with a 'Buy' rating, citing the company's structural competitive Moats, strong monetisation runway, and accelerating path to profitability

Park Medi World IPO: Analysts split on prospects; should you apply?

The three-day subscription window to bid for the Park Medi World IPO will close on Friday, December 12, 2025